Oye, igual es un cierre de cortos recomprando, aprovechando que hay calamares que las venden al 10.04. Joer, yo es que no me explico las operaciones de los AH, algún dia entenderé porqué la gente compra y vende a esos precios.
Cuando lo entiendas, nos lo explicas ¿vale? jajaja.
Buen día para NVAX, a mi el AH me la ...
AMRN segundo día dn rojo, a ver mañana
Pues supongo que en ese caso, el que ha vendido los 30000 cromos, ha puesto la órden a mercado; y el que ha comprado, habrá puesto la órden limitada a 10,04. Pero joder, es que la gente que compra o vende a mercado tanto en el AH como en el pre, les debe faltar un hervor; o eso, o son trapicheos entre peces gordos.
NVAX
Aperitivo de RSV maternos/bebés con un preclínico con cobayas... lo mejor es que se vuelve a insistir en que los resultados que todos esperamos estarán este trimestre ; )
.
.
.
Novavax (NASDAQ: NVAX) announced its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.1
Direct immunization of infants is complicated by their immature immune systems which are unable to fight off viral infection early in life when infants are most vulnerable to RSV. In mammals, the passage of maternal antibodies to offspring is largely achieved either by in utero transplacental transfer of immunoglobulin G antibodies (IgG) or by postpartum breast-feeding of colostral milk containing high levels of IgG and sIgA.2 For human infants, maternally-derived IgG appears to be provided entirely in utero, via transplacental Fc receptor-mediated antibody transfer.2 The protective effects of human serum IgG, transferred from mothers to infants in utero,2 against a number of infections, including influenza and pertussis, has been well-described.3-5
Presumptive pregnant guinea pigs were immunized with the RSV F Vaccine on gestational days 25 and 46. The vaccine induced high levels of anti-F IgG antibodies, palivizumab-competing antibodies (PCA) and microneutralizing titers. The peer-reviewed manuscript also demonstrates transfer of placental anti-RSV antibodies, as measured by a number of immunoassays, at days 15 and 30 postpartum.
“RSV is the leading cause of infant hospitalizations in the U.S. and a significant unmet need in full-term infants,” said Gregory M. Glenn, M.D., Senior Vice President, Research and Development at Novavax. “The placental architecture in guinea pigs reflects the anatomy found in humans, making them an appropriate model to evaluate placental transfer of antibodies. These preclinical data further support our RSV F Vaccine maternal immunization program, and we look forward to announcing data from our Phase 2 clinical trial to protect infants via maternal immunization this quarter.”
NVAX
A 10.63 en el AH ahora. Así que los mantuviera en el PM, eso y más, y un halted en apertura, jajaja.
Edito: Joer, voy a traducir lo que has puesto, Kiyo, a ver si es bueno.
Edito: Pues parece que son avances favorables con los bichos.
Edito más: Y parecía tonto el que ha comprado las 30.000 a 10.04.
Al final que, tiró para arriba o que.je je THLD
Un saludo.
Hoy estuve desconectado.
NVAX
Pero has visto "qué superbloques" ?? jajaja
Ahora marca 10.86$ pero el volumen es una miseria.
http://www.nasdaq.com/es/symbol/nvax/after-hours
